Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 20 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 7 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

N/A
6(100.0%)
6Total
N/A(6)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (20)

Showing 20 of 20 trials
NCT07539324Not ApplicableNot Yet Recruiting

Clinical Impact of DCB-based Versus DES-based Intervention in Patients With MVCAD

Role: lead

NCT07431437Enrolling By Invitation

One-Year Results of GENOSS PCB Real-World Study in Femoropopliteal Artery Disease

Role: lead

NCT07425171Not Yet Recruiting

Safety and Effectiveness of GENOSS PCB in Patients With Long Femoropopliteal Lesion

Role: lead

NCT07399080Enrolling By Invitation

Clinical Outcomes of GENOSS PCB for Femoropopliteal Artery Disease

Role: lead

NCT06075368Active Not Recruiting

Efficacy and Safety of GENOSS® SES in Patients With Acute Coronary Syndrome (GENOSS ACS)

Role: lead

NCT05448625Completed

Genoss DES in Patients With a High Risk of Ischemic Events (GENTLE Registry)

Role: collaborator

NCT06168305Enrolling By Invitation

Safety and Effectiveness of GENOSS® DES in Patients With Multivessel Coronary Artery Disease

Role: lead

NCT06086496Enrolling By Invitation

Effectiveness and Safety of Abluminal Biodegradable Polymer Sirolimus-eluting Stent (GENOSS® DES)

Role: lead

NCT06841510Active Not Recruiting

Efficacy and Safety of GENOSS SES in Patients With Coronary Artery Disease

Role: lead

NCT07159087Not ApplicableEnrolling By Invitation

The Safety and Efficacy for In-segment Late Lumen Loss of the 'Genoss® SCB' Versus 'SeQuent® Please NEO' in Patients With Coronary ISR

Role: lead

NCT07158307Enrolling By Invitation

Safety and Efficacy of GENOSS® DCB With a Shellac Plus Vitamin E Excipient in Patients With De Novo Lesion

Role: lead

NCT04767022Not ApplicableCompleted

Compare the Safety and Effectiveness of Genoss® DCB and SeQuent® Please NEO in Chinese Patients with Coronary ISR

Role: lead

NCT06075433Recruiting

Efficacy and Safety of 1-year Duration of DAPT After GENOSS® DES Implantation in Patients with Coronary Artery Disease According to the Complex Higher-risk Procedure

Role: lead

NCT06075420Recruiting

Efficacy and Safety of Short Duration of DAPT After GENOSS® DES Implantation in Patients with Coronary Artery Disease

Role: lead

NCT06066476Completed

Efficacy and Safety of GENOSS® DES in Patients with Coronary Artery Disease

Role: lead

NCT05134545Not ApplicableCompleted

Compare the Effectiveness and Safety of Genoss® DCB and IN.PACT Admiral® DCB in Patients With Peripheral Artery Disease

Role: lead

NCT05096442Not ApplicableCompleted

Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Korean Patients With Coronary De Novo Lesions

Role: lead

NCT04405063Not ApplicableCompleted

Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please in Korean Patients With Coronary In-stent Restenosis

Role: lead

NCT06066450Recruiting

Efficacy of OSFIT Drug-Eluting Stent in Coronary Ostial Artery Stenosis

Role: lead

NCT03045913Completed

Genoss DES Prospective Multicenter Registry

Role: collaborator

All 20 trials loaded